PPARα ligands such as fenofibrate, bezafibrate, and gemfibrozil are well kown hypolypidemic drugs and thus, they can improve clinical consequences of metabolic disorders asocciated with increased cancer risk. This evidence concerns the gene PPARA and Other metabolic disease.